Abstract:CDKL5 deficiency disorder (CDD) is a genetic disease that produces lifelong neurological dysfunction, including autism, intellectual disability and epilepsy. This study employed a clinically relevant mouse model of CDD to investigate the effects of cannabidiol (CBD) on behavioural outcomes and found that it attenuates seizure susceptibility, memory impairments and social behavioural deficits. The clinical impact of this research is potentially very high, as CBD is already FDA‐approved for epilepsy. The study also demonstrates altered signalling related to the endogenous endocannabinoid system in CDD, which could inform the development of novel therapies with more specific endocannabinoid receptor modulators. Cyclin‐dependent kinase‐like 5 (CDKL5) deficiency disorder (CDD) is caused by a loss‐of‐function mutation in CDKL5 gene, encoding a serine–threonine kinase highly expressed in the brain. CDD manifests with early‐onset epilepsy, autism, motor impairment and severe intellectual disability. While there are no known treatments for CDD, the use of cannabidiol has recently been introduced into clinical practice for neurodevelopmental disorders. Given the increased clinical utilization of cannabidiol, we examined its efficacy in the CDKL5R59X knock‐in (R59X) mice, a CDD model based on a human mutation that exhibits both lifelong seizure susceptibility and behavioural deficits. We found that cannabidiol pre‐treatment rescued the increased seizure susceptibility in response to the chemoconvulsant pentylenetetrazol (PTZ), attenuated working memory and long‐term memory impairments, and rescued social deficits in adult R59X mice. To elucidate a potential mechanism, we compared the developmental hippocampal and cortical expression of common endocannabinoid (eCB) targets in R59X mice and their wild‐type littermates, including cannabinoid type 1 receptor (CB1R), transient receptor potential vanilloid type 1 (TRPV1) and 2 (TRPV2), G‐coupled protein receptor 55 (GPR55) and adenosine receptor 1 (A1R). Many of these eCB targets were developmentally regulated in both R59X and wild‐type mice. In addition, adult R59X mice demonstrated significantly decreased expression of CB1R and TRPV1 in the hippocampus, and TRPV2 in the cortex, while TRPV1 was increased in the cortex. These findings support the potential for dysregulation of eCB signalling as a plausible mechanism and therapeutic target in CDD, given the efficacy of cannabidiol to attenuate hyperexcitability and behavioural deficits in this disorder.

Neurophysiological and brain structural insights into cyclin-dependent kinase-like 5 deficiency disorder: Visual and auditory evoked potentials and MRI analysis

Brain morphological abnormalities in children with cyclin-dependent kinase-like 5 deficiency disorder

Exploring quality of life in individuals with a severe developmental and epileptic encephalopathy, CDKL5 Deficiency Disorder

Longitudinal, multidimensional, observational study of 15 patients with CDKL5 Deficiency Disorder

CDKL5 deficiency disorder: Relationship between genotype, epilepsy, cortical visual impairment, and development

Psychometric evaluation of clinician- and caregiver-reported clinical severity assessments for individuals with CDKL5 deficiency disorder

Neuronal hyperexcitability and ion channel dysfunction in CDKL5-deficiency patient iPSC-derived cortical organoids

Communication of individuals with CDKL5 deficiency disorder as observed by caregivers: A descriptive qualitative study

CDKL5 deficiency-related neurodevelopmental disorders: a multi-center cohort study in Italy

CDKL5 Deficiency Disorder-Related Epilepsy: A Review of Current and Emerging Treatment

Novel CDKL5 targets identified in human iPSC-derived neurons

In vivo magnetic resonance spectroscopy in the brain of Cdkl5 null mice reveals a metabolic profile indicative of mitochondrial dysfunctions

To explore the potential mechanisms of cognitive impairment in children with MRI-negative pharmacoresistant epilepsy due to focal cortical dysplasia: A pilot study from gray matter structure view

Excitatory Cortical Neurons from CDKL5 Deficiency Disorder Patient-Derived Organoids Show Early Hyperexcitability Not Identified in Neurogenin2 Induced Neurons

Altered Cerebello‐Motor Network in Familial Cortical Myoclonic Tremor with Epilepsy Type 1

Enhanced hippocampal LTP but normal NMDA receptor and AMPA receptor function in a rat model of CDKL5 deficiency disorder

Epileptic spasms in CDKL5 deficiency disorder: Delayed treatment and poor response to first-line therapies

Effects of a ciliary neurotrophic factor (CNTF) small-molecule peptide mimetic in an in vitro and in vivo model of CDKL5 deficiency disorder

Delineation of Structural Rearrangements as an Overlooked Recurrent Pathological Mechanism

Cannabidiol attenuates seizure susceptibility and behavioural deficits in adult CDKL5R59X knock‐in mice

Deletions in the CDKL5 5′ untranslated region lead to CDKL5 deficiency disorder